

Nuchev Limited Investor Presentation

May 2020, Wilsons Rapid Insights Conference



Today's presenters



Ben Dingle
CEO, Executive Director and Founder



Chantelle Pritchard
CFO and Company Secretary



Agenda

Business strengths	3
Financial and business highlights	4
Key financial and operational metrics	5
Appendix	7

Business strengths



Significant global market opportunity

- Goat milk based infant formula (GIF) is a rapidly growing segment of the infant formula (IF) market
- Global GIF market is forecast to grow at an estimated CAGR of 16.6% to A\$13.6 billion by 2023, predominantly driven by the Chinese market¹



High quality, established supply chain & distribution network

- Quality, secure and scalable supply chain - capital light model, with significant excess capacity
- Utilises leading manufacturing partners with necessary certifications and expertise
- Supply chain expertise supported by Nuchev's significant in-house experience & capability



Premium, differentiated product, supported by science

- GIF offers natural health benefits to infants
- Attractive to health conscious end consumers (key group is Chinese mothers) prepared to pay a premium for differentiated products
- RMIT University published scientific laboratory studies supporting the potential health benefits of Oli6^{®2}



Proven management and board with deep industry expertise

- Founded and led by Ben Dingle, co-founder of Synlait Milk, processing partner of a2 Milk
- Supported by experienced management team and Board, with deep knowledge of the IF sector and channels to market



Oli6[®] is a premium, trusted, Australian made and owned brand

- Oli6[®] is Australian made and has demonstrated success in domestic Australian and Chinese markets
- Oli6[®] brand benefits from the premium position of GIF, with growing awareness of GIF health benefits
- Brand positioning attractive to Chinese mothers and channel partners



Significant volume and revenue growth

- Nuchev has and continues to achieve significant sales volume and revenue growth including exceeding 1H20 Prospectus forecasts
- Potential upside from sales of China-specification product (subject to SAMR brand registration)


Sources

1. Frost & Sullivan, *The Infant Formula Market*, October 2019.
2. Leong, A., Liu, Z., Almshawit, H., Zisu, B., Pillidge, C., Rochfort, S., & Gill, H. (2019). *Oligosaccharides in goats' milk-based infant formula and their prebiotic and anti-infection properties*. British Journal of Nutrition, 122(4), 441-449.


Financial and business highlights



Volumes (metric tonnes)



Revenue (\$M)



1. Q3 FY20's performance includes Chinese New Year with typically low sales during that month, and in direct contrast to Q2 which includes Singles Day (11/11) the largest annual promotional event.

Continued revenue and volume growth

- Strong sales momentum of Nuchev's Oli6® goat-milk infant formula and nutritional products
- Volume and Revenue for the 9 months ending March 2020 was up 168% and 153% respectively compared with PcP
- Q3 FY20 volumes and net revenue increased by 87% and 78% over the PcP driven by increasing penetration across Nuchev's key distribution channels.
- March 2020 was an all-time record sales month for Nuchev
- 1H20 Revenue and Volumes exceeded 1H20 Prospectus forecast

Strong balance sheet, positioned for growth

- No debt, net cash reserves of \$13 million (31 March 2020)
- Q3 reflected a strong quarter on quarter improvement in operating cash flows

Other

- No adverse material impacts from COVID-19
 - strong market demand
 - capably met by Nuchev's high quality supply chain

Key financial and operational metrics



	9 months ending Mar20 ⁶	Full Year Prospectus forecast ⁵	9 months ending Mar19 (PcP)	% Change
Volume (MT) ¹	418	573	156	168%
Revenue (\$ million) ¹	\$13	\$18	\$5.1	153%
Core volume (MT) ²	392	573		
Core revenue (\$ million) ²	\$12	\$18		
ASP/MT (\$ thousands) ³	31	31		
Gross Margin% ⁴	39%	38%		
Marketing % of Revenue	39%	30%		
CAPEX % of Revenue	-	-		

Notes:

1. Revenue / volume reflects the sale of GIF, other goat nutritional products and raw ingredient sales.
2. Core revenue / volume is from Australia-specification GIF and Goat Milk Powder only and excludes goat milk sales and raw ingredient sales.
3. Average selling price per MT represents the total revenue of Australia-specification GIF and Goat Milk Powder sold divided by the total volume of Australia-specification GIF and Goat Milk Powder sold.
4. Gross Margin is calculated as core revenue, less costs of sales divided by core revenue, expressed as a percentage.
5. Prospectus forecasts relate to the full year.
6. Unaudited results before statutory adjustments for the 9 months ending 30 March 2020.

Commentary

- Continued strong Volume and Revenue growth for the 9 months ending March 2020 compared with PcP - Volume up 168%; Revenue up 153%
 - 1H20 Volume and Revenue exceeded half year Prospectus forecasts by 10% and 7% respectively. This included sale of surplus ingredients as part of typical inventory balancing. Excluding these sales, 1H20 Volumes were 3% ahead and Revenue was in line with Prospectus forecast
- ASP/MT is in line with full year Prospectus forecast
- Gross Margin is in line with full year Prospectus forecast
- Marketing % of Revenue remains ahead of full-year Prospectus forecast driven by:
 - Investment in brand to meet market conditions, leverage growth opportunities and recognising the importance of building brand equity at Nuchev's relatively early stage; and
 - Full, upfront expense of distributor equity (subject to agreed volume thresholds) compared with Prospectus forecast which expensed this cost over the agreement's initial multi-year term
- CAPEX % of Revenue is in line with full year Prospectus forecast reflecting Nuchev's capital light model
- Cost base is relatively fixed, and Nuchev expects to continue to benefit from operating leverage as the business scales



Appendix



Strategy – 3 key pillars



Brand positioning & awareness

- Invest in building brand equity amongst channel partners and end consumers
- Key brand factors:
 - product safety and quality;
 - International brand backed by deep history;
 - Super premium, differentiated health and nutritional benefits backed by science
 - positioned as experts in the GIF category

Product quality and nutritional development

- Laser focus on quality of product, through ingredient sourcing, manufacturing, distribution and support
- Dedicated to continual nutritional development of goat milk based products
- Differentiated health benefits and quality of Nuchev's GIF and goat nutritional products as a key competitive advantage
- Nutritional development founded upon product innovation supported by scientific research

Multi-channel sales strategy and channel support

- Leveraging existing distributor relationships to drive sales
- Increased penetration of the CBEC channel
- Expansion into other international markets
- Rapid growth of China-specification product sales based on contracts in place, subject to SAMR brand registration

Nuchev's Oli6® GIF range



The product range covers the full age spectrum and development requirements

Stage 1 formula
(0-6 months)



Stage 2 formula
(6-12 months)



Stage 3 formula
(1-3 years)



Stage 4 formula
(3-7 years)



Goat Milk Powder
(adult)



Oli6's value proposition is differentiated and compelling to end consumers



Health benefits supported by research



- Oli6® offers credible, differentiated health benefits
- Scientific laboratory research on the health benefits associated with oligosaccharides in Oli6®¹

Peer-to-peer endorsement



- Rapidly growing consumer base – Oli6® products are loved by infants and children
- Industry leading peer-to-peer endorsement of Oli6® – important for driving demand from Chinese mothers

Strong Brand: Premium product, Australian made and owned



- Premium, trusted product that is reliable and safe
- Oli6® is made in Australia, and has an established presence in prominent Australian pharmacy (Chemist Warehouse) and grocery (Coles) outlets

Experts on goat milk products




- Exclusively focused on goat based nutritional products
- Founder led by 4th generation farmer with deep industry experience and demonstrated success with Chinese parties

Sources:

1. Leong, A., Liu, Z., Almshawit, H., Zisu, B., Pillidge, C., Rochfort, S., & Gill, H. (2019). *Oligosaccharides in goats' milk-based infant formula and their prebiotic and anti-infection properties*. British Journal of Nutrition, 122(4), 441-449.

Capital light business model focuses on quality, security and scalability



*Nuchev has developed and owns all of its proprietary product specifications, processes and know-how and has control over the chemical and microbiological specifications of its products across the supply chain

Flexible supply chain delivers competitive advantage



Supply Chain

1

Highest quality materials

- Direct goat ingredient supply from the Netherlands, the centre of excellence for goat
- Positively perceived by Chinese and other end consumers – Dutch goat industry is highly reputable and reliable

2

Flexibility

- Goat materials imported in stable powder form with long shelf-life (contrast with fresh milk challenges)
- Production flexibility - suited to meeting rapidly growing demand and managing supply chain risk

3

Quality control

- Stage gated quality control and stringent testing regime throughout the supply chain focused on delivering highest quality
- Leverages Nuchev's goat expertise in conjunction with industry leading strategic outsourced partners

4

Cost competitive

- Imported ingredients cost competitive with Australian sourced ingredients (local industry developing and processing assets not specifically designed for goat)
- Nuchev retains farming optionality (owns ~2,500 goats and has demonstrated expertise)

5

Capital-light

- Cost-efficient capital-light business model
- Investment in premium brand positioning and developing multi-channel distribution partnerships where the majority of valuation creation occurs

6


Significant excess capacity

- Significant excess supply chain capacity
- Complemented by supplemental raw ingredient & processing alternatives in place

Multiple sales channels ensures efficient routes to market and reduces risk




Australian-specification



Oli6® current sales across these channels

China-specification



Oli6 is an attractive value proposition to distribution channel partners



Distribution chain

1

GIF is a premium and differentiated IF product

- Oli6® has differentiated health benefits and a strong brand position
- Allows positioning as a premium product attracting higher margins

2

Growing consumer awareness is driving end consumer demand

- Nuchev delivers targeted marketing spend into Chinese end consumers
- This drives 'pull' demand from within China and is beneficial to channel partners

3

Oli6® is a premium, trusted, Australian-made and owned brand

- Distribution reach and sales via prominent Australian retailers helps position Oli6® as a trusted GIF brand
- Australian brands are well regarded

4

GIF is a fast-growing market segment

- Oli6® offers channel partners exposure to the rapidly growing GIF market, with a proven product
- Demonstrated acceptance by Chinese end consumers

5

Limited competition, supporting margins

- Limited foreign owned GIF competition compared to cow's milk IF – less pricing pressure
- Greater opportunity for strong margins for channel partners

6

Quality record and secure supply chain

- High quality record demanded by channel partners who are investing in the brand
- Nuchev has a demonstrated quality record with an established supply chain focused on quality and aligned to industry best practice

Disclaimer



This presentation is provided by Nuchev Limited (ACN 163 225 090) (Nuchev) to provide summary information about Nuchev and its respective subsidiaries (together, the Group). Statements in this presentation are made as at the date of the presentation and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes and should not be relied upon by the recipient. This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient.

Recipients should carry out their own investigations and analysis of the Group and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in Nuchev.

No liability: To the maximum extent permitted by law, none of Nuchev, the Group or their respective affiliates or related bodies corporate or any of their respective officers, directors, employees and agents (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, Nuchev, the Group or Nuchev securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

Not financial product advice: Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not a financial product or investment advice or recommendation to acquire Nuchev securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in Nuchev and should not rely on this presentation. In all cases, you should conduct your own research of Nuchev and the Group and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of Nuchev, the Group and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

Past performance: Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as an indication of future performance.

Future performance: This presentation contains certain forward-looking statements with respect to the financial condition, operations and business of the Group and certain plans and objectives of the management of Nuchev. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms “believes”, “estimates”, “anticipates”, “expects”, “predicts”, “intends”, “plans”, “goals”, “targets”, “aims”, “outlook”, “guidance”, “forecasts”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which because of their nature may cause the actual results or performance of the Group to be materially different from the results or performance expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group’s present and future business strategies and the political and economic environment in which the Group will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts. To the full extent permitted by law, Nuchev, the Group and their respective affiliates and related bodies corporate and each of their respective Related Parties and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Financial data: All figures in the presentation are Australian Dollars unless stated otherwise.